Inclisiran + Evolocumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Atherosclerotic Cardiovascular Disease
Conditions
Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes, Familial Hypercholesterolemia
Trial Timeline
Apr 27, 2017 → Dec 17, 2021
NCT ID
NCT03060577About Inclisiran + Evolocumab
Inclisiran + Evolocumab is a phase 2 stage product being developed by Novartis for Atherosclerotic Cardiovascular Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03060577. Target conditions include Atherosclerotic Cardiovascular Disease, Symptomatic Atherosclerosis, Type2 Diabetes.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03060577 | Phase 2 | Completed |
Competing Products
20 competing products in Atherosclerotic Cardiovascular Disease